Can a smartphone app help teens kick the vape habit?
NCT ID NCT06965296
First seen Jun 27, 2026 · Last updated Aug 07, 2026 · Updated 3 times
Summary
This study tests whether a smartphone app with AI can help adolescents aged 14-20 quit e-cigarettes. Participants use the app to set goals, track progress, and get real-time support during cravings. Researchers compare an immediate-use group with a delayed-start group to see if the app improves quitting success.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- AI-enhanced smartphone app
- What this could lead to
- If it works, this could provide an accessible, personalized tool to help adolescents quit e-cigarettes and reduce nicotine dependence.
- What could go wrong
- This is a small, early-stage study with only 100 participants, so results may not apply to everyone. The app's success depends on user engagement, and quitting is difficult even with support.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 100 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Aug 2026
An estimate. Start dates often move.
- Expected to finish
-
Jun 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
14 to 20 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria * Adolescents who are 14 to 20 years old * Currently use nicotine-containing e-cigarettes (those responding "Yes" to: Have you used an electronic vaping product such as PuffBar, ElfBar, Lost Mary, JUUL, Vuse, e-cigarettes, vapes, vape pens, e-cigars, e-hookahs, hookah pens, or mods at least 1 day in the last 30 days? \[CDC, 2020\]) * Interested in participating in an e-cigarette use cessation program * Owners of an iPhone or Android smartphone who use their phone daily * Able to read English Exclusion Criteria * Individuals who fall outside the age range of 14 to 20 years * Those who have not used a nicotine-containing e-cigarette in the past 30 days * Individuals not interested in participating in an e-cigarette cessation program * Adolescents who do not own or regularly use an iPhone or Android smartphone * Non-English speakers
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Nicotine dependence, cigarettes are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
University at Buffalo, School of Nursing
Buffalo, New York, 14214, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.